ReviewCroatian medical journal2014
Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis.
Review in Croatian medical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 52 citations in OpenAlex.
- Prognostic implications of one-year left ventricular systolic function after heart transplantation.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Regulated cell death in organ transplantation: recent developments and mechanistic overview.Journal of molecular cell biology · 2026Review
- Article
- Gender in post-cardiac transplant patients has no effect on the occurrence of death, major cardiovascular events or development of cardiac allograft vasculopathy.American journal of cardiovascular disease · 2025Article
- A Machine Learning Framework for Diagnosing and Predicting the Severity of Coronary Artery Disease.Reviews in cardiovascular medicine · 2023Article
- Elevated Plasma Immunoglobulin Levels Prior to Heart Transplantation Are Associated with Poor Post-Transplantation Survival.Biology · 2022Article
- Heart transplant recipient 1-year outcomes during the COVID-19 pandemic.Clinical transplantation · 2022Article
- Far-Infrared Therapy Decreases Orthotopic Allograft Transplantation Vasculopathy.Biomedicines · 2022Article
- Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats.Cardiovascular drugs and therapy · 2021Article
- Transplanted stents: a case report.BMC cardiovascular disorders · 2020Article
- Multi-gene technical assessment of qPCR and NanoString n-Counter analysis platforms in cynomolgus monkey cardiac allograft recipients.Cellular immunology · 2020Article
- Erythroblast transformation-specific 2 correlates with vascular smooth muscle cell apoptosis in rat heterotopic heart transplantation model.Journal of thoracic disease · 2016Article
- Contemporary challenges in the management of advanced heart failure.Croatian medical journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of cardiac allograft vasculopathy represents the major determinant of long-term survival in patients after heart transplantation. Due to graft denervation, these patients seldom present with classic symptoms of angina pectoris, and the first clinical presentations are progressive heart failure or sudden cardiac death. Although coronary angiography remains the routine technique for coronary artery disease detection, it is not sensitive enough for screening purposes. This is especially the case in the first year after transplantation when diffuse and concentric vascular changes can be easily detected only by intravascular ultrasound. The treatment of the established vasculopathy is disappointing, so the primary effort should be directed toward early prevention and diagnosis. Due to diffuse vascular changes, revascularization procedures are restricted only to a relatively small proportion of patients with favorable coronary anatomy. Percutaneous coronary intervention is preferred over surgical revascularization since it leads to better acute results and patient survival. Although there is no proven long-term advantage of drug-eluting stents for the treatment of in-stent restenosis, they are preferred over bare-metal stents. Severe vasculopathy has a poor prognosis and the only definitive treatment is retransplantation. This article reviews the present knowledge on the pathogenesis, diagnosis, treatment, and prognosis of cardiac allograft vasculopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.